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Abstract: IDARS is an acronym for the International Drug Abuse Research Society. Apart from our scientific and educa-
tional purposes, we communicate information to the general and scientific community about substance abuse and addic-
tion science and treatment potential. Members of IDARS are research scientists and clinicians from around the world, 
with scheduled meetings across the globe. IDARS is developing a vibrant and exciting international mechanism not only 
for scientific interactions in the domain of addiction between countries but also ultimately as a resource for informing 
public policy across nations. Nonetheless, a lot more research needs to be done to better understand the neurobiological 
basis of drug addiction – A challenge for IDARS scientists. 
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INTRODUCTION 
  Drug addiction is a chronically relapsing disorder that 
has been characterized by the compulsive use of addictive 
substances despite adverse consequences to the individual 
and society [1]. Addiction to drugs and alcohol is 
increasingly becoming a worldwide trend in lifestyle that is 
prevalent in rich and poor countries alike. Addiction to 
alcohol, drugs and cigarette smoking is now regarded as a 
major public health problem. Other forms of addiction 
including computer games, gambling, sex and food also have 
severe consequences on the health of the individual and to 
society. The commonly abused drugs have profound action 
in the nervous system, particularly in the brain. Some of 
these substances such as opium, marijuana, cocaine, nicotine, 
caffeine, mescaline, and psilocybin are obtained from natural 
sources while others are synthetic or designer drugs. 
Furthermore some of these substances like alcohol and 
nicotine are legal while some others that are legally available 
by prescription have addictive potential in vulnerable 
individuals. A number of addictive substances are illegal in 
most countries and this fuel the illegal drug trafficking and 
business that are often associated with criminal activities. 
The initiation of the use of these substances induces 
euphoria, reward and a state of well-being that can lead   
to physical and psychological dependences. Withdrawal 
syndrome occurs when the individual attempts to stop the 
use of addictive substances and this leads to the cycle of 
dependency. The mechanism(s) associated with the cycle of 
addiction include neuronal adaptation with tolerance or 
sensitization involved in the action of addictive substances. 
A number of factors have also been associated with   
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addiction, including the availability, cost, method of 
administration, environmental factors such as behaviors 
acceptable in a community, peer influences and genetic and 
epigenetic factors. Over the years a number of therapeutic 
approaches for drug and alcohol addiction have been 
utilized. However, relapse the resumption of drug taking 
following a period of drug abstinence, is considered the main 
hurdle in treating drug addiction. Unfortunately pharma- 
cological treatment of drug and alcohol dependency has 
largely been disappointing and new therapeutic targets and 
hypotheses are needed. Drug addiction is also influenced by 
the interaction of genes, epigenetics and the environment. 
Twin studies consistently show that there is a heritable 
component to drug abuse and addiction [2]. Now using 
modern genomic techniques, we are able to examine genetic 
variants, or single nucleotide polymorphisms that contribute 
to addiction vulnerability. So a lot more research needs to be 
done to better understand the neurobiological basis of drug 
addiction and hence a continuous challenge for IDARS 
scientists. IDARS is therefore engaged in a vibrant and 
exciting international mechanism, not only for scientific 
interactions among scientists in the domain of addiction 
research between countries but also as a resource for inform- 
ing public policy across nations. This is an exciting period in 
the study of the neurobiology of addiction where brain 
circuitry and molecular mechanisms are providing hope for 
understanding not only the vulnerability to addiction but also 
providing new targets for the treatment of various types of 
substance abuse/dependence as presented in this report. 
MARIJUANA HIGHLIGHTS 
  Various forms of marijuana preparations comes from the 
cannabis plant and is the most commonly used drug in the 
world, for recreation and suddenly, we are awakened to 
potential therapeutic applications. Therefore, these are high Understanding the Global Problem of Drug Addiction is a Challenge  Current Neuropharmacology, 2011, Vol. 9, No. 1    3 
times for marijuana research with new findings on the 
biological effects of cannabinoids and as new potential 
applications in neurological and neuropsychiatric disorders 
[3]. The new advances and understanding indicate that the 
cellular, molecular and behavioral responses to marijuana are 
encoded in our genes [3]. The discovery that specific genes 
codes for cannabinoid receptors (CBRs) that are activated by 
marijuana use, and that the human body makes its own mari-
juana-like substances - endocannabinoids [4], that also acti-
vates CBRs have provided surprising new knowledge about 
cannabinoid genomic and proteomic profiles. These remark-
able advances in understanding the biological actions of 
marijuana, cannabinoids and endocannabinoids, is unravel-
ing the genetic basis of marijuana use and the implication in 
human health and disease. We know that the two well char-
acterized cannabinoid CB1 and CB2 receptors are encoded 
by CNR1 and CNR2 genes that have been mapped to human 
chromosome 6 and 1 respectively. A number of variations in 
cannabinoid receptor genes have been associated with human 
disorders including drug dependency [4], osteoporosis [5], 
ADHD and PTSD, [6, 7], obesity [8, 9], and depression [10, 
11]. Thus, because of the ubiquitous distribution and role of 
the endocannabinoid system in the regulation of a variety of 
normal human physiology, drugs that are targeted to differ-
ent aspects of this system are already benefiting cancer sub-
jects and those with AIDs and metabolic syndromes [8]. In 
the coming era of personalized medicine, genetic variants 
and haplotypes in CNR1 and CNR2 genes associated with 
obesity or addiction phenotypes may help identify specific 
targets in conditions of endocannabinoid dysfunction. Most 
strikingly, variants of CNR genes co-occur with other genetic 
variations and share biological susceptibility that underlies 
comorbidity in many neuropsychiatric disturbances [12]. 
Therefore, understanding the endocannabinoid system in the 
human body and brain will contribute to elucidating this 
natural regulatory mechanism in health and disease. 
CHRONIC ALCOHOLISM IN HUMAN SUBJECTS 
  Illicit drug use has well-known detrimental effects, but 
the legal drugs tobacco and alcohol have far greater impact 
on human health world-wide. By a standard measure of mor-
bidity, DALYS, tobacco is at 4.1%, alcohol 4.0% (6.6% for 
males, 3.1% for females [13]); all illicit drugs combined add 
only 0.8% to global disease burden [14]. Alcohol consump-
tion is common: in one survey, 82% of respondents over 14 
had imbibed it in the previous 12 months [15]. The social 
cost of alcohol use is also very high [16, 17]. Alcohol misuse 
leads to selective brain pathology, though subjects differ 
markedly [18]. Brain shrinkage, reduced white-matter vol-
ume, and dendritic pruning may be reversible with absti-
nence; irreversible effects are more focal: superior prefrontal 
cortex (SFC) is particularly vulnerable [19, 20]. Common 
comorbidities (cirrhosis of the liver and the Wernicke-
Korsakoff syndrome), which are more prevalent with higher 
rates of alcohol consumption [21], lead to greater brain atro-
phy [18]. Neuronal death may be due to excitotoxicity, an 
imbalance between excitatory and inhibitory inputs mediated 
by NMDA receptors (NMDAR) and reduced GABAA-
mediated responses [22, 23]. This allostasis [24, 25] main-
tains a proper balance between excitation and inhibition in 
the presence of alcohol. When alcohol is removed, as in pe-
riods of abstinence, the balance is skewed towards over-
excitation. This leads to a large influx of Ca
2+ ions into cells, 
affecting many signaling pathways and eventually leading to 
cell death. In rat and mouse models NMDAR are increased 
after chronic alcohol, but there are regional and species dif-
ferences due to modes of administration, age, time of with-
drawal, etc [26-29]. All studies show increases in at least one 
NMDAR subunit [30-34]. However, the area affected and 
the subunit(s) that change are paradigm-dependent [30, 32]. 
  In human autopsy studies, NMDAR are increased in SFC 
and hippocampus [35, 36]. Alcoholics without comorbid 
disease shift the excitatory balance by GABAA receptor 
subunit switching to reduce inhibitory function. GABAA 
shifts are small in cirrhotic alcoholics, and the key change 
may be increased excitability via altered NMDAR expres-
sion. Using quantitative real-time PCR we found that alco-
holics without liver cirrhosis did not differ significantly from 
controls in the expression of any subunit, whereas all 
subunits were significantly lower in cirrhotic alcoholics [37-
40]. Promising NMDAR-specific tracers for PET and 
SPECT provide the potential to study NMDAR changes in 
human subjects in the future [41-43]. 
  Chronic alcohol misuse affects the expression of many 
genes in the brain, leading to long-term changes in neural 
function. Microarray and proteomic studies have found 
changes in the expression of genes involved in metabolism, 
immune response, cell survival, cell communication, signal 
transduction, and energy production, DNA-binding proteins, 
transcription factors, repair enzymes, myelination, and cell-
adhesion [44-46]. 
The Genetics of Alcoholism 
  Alcoholism in human subjects is mediated by many so-
cietal and genetic factors. Genes may mediate etiology and 
pathogenesis, although this issue is still hotly debated. Dif-
ferent genetic markers are associated with increased risk of 
alcohol misuse, dependence, craving, tolerance, and with-
drawal severity [47]. Risk-factor genes code for alcohol-
metabolising enzymes, and also for the effectors of neuro-
transmission – receptors, transporters and signal-transduction 
components – for a variety of transmitter classes, including 
dopamine, serotonin, glutamate, and GABA. Some genes are 
associated with general aspects of addiction [48, 49]. 
  The effects of these polymorphisms can be divided into 
two categories: those that pre-dispose the individual to alco-
hol abuse, and those that make an individual more suscepti-
ble to the toxic effects of alcohol. Polymorphisms may not 
only alter the product of the parent gene (e.g., by changing 
the amino-acid codon) but may also have pleiotropic effects, 
i.e., the changes in one gene may affect the expression of, or 
activity of the product of, another gene. An emerging mi-
croarray literature is showing that knocking out a single gene 
alters the expression of hundreds of transcripts, many of 
which have no discernible association with the knocked-out 
gene. Knockout mice strains that differ in alcohol respon-
siveness have been compared to find transcripts that show 
discriminant expression [50]. Affected transcripts are from 
genes located on a range of chromosomes – not only that 
bearing the knocked-out gene. It is difficult to transfer this 
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relevant to human alcoholism is the ALDH2 gene (ALDH2-
2,2 homozygotes have no ALDH activity [51]). More gener-
ally, allelic variants of alcoholism-associated genes are very 
likely to moderate the expression of a range of genes. There 
is a multiplier effect for expression whereby proteins usually 
show larger effect sizes than mRNA transcripts [52]: pro-
teins are more readily linked to functional differences than 
transcripts. 
Dopamine and Alcohol 
  Dopamine (DA) is a monoamine transmitter that medi-
ates motivation, attention, short-term memory and rein-
forcement. Many dopaminergic neurones originate in the 
ventral tegmental area (VTA) and project to the cerebral cor-
tex, nucleus accumbens (NAc) and amygdala [53]. The 
mesolimbic system of the brain has been a focus of addiction 
research because it involves the so-called pleasure-centers 
such as the NAc. Dopaminergic transmission in this system 
may play a central role in many, if not all, addictions [54]. 
Animal studies show a dose-dependent increase in DA in 
response to alcohol in the NAc, indirectly mediated via the 
VTA. An increase in DA in the NAc occurs in conditioned 
animals in anticipation of ethanol administration. The local 
application of dopaminergic-specific neurotoxins in the NAc 
can lead to a reduction in ethanol consumption in alcohol-
dependent rats. In human subjects, PET studies show a sig-
nificant decrease in DA D2 receptor binding in alcoholics. 
Alcoholics also show reduced dopaminergic function that 
correlates with addiction severity. Despite these observa-
tions, DA agonists and antagonists have had limited success 
as treatments for alcoholism [55]. 
Genetic variation in DRD2 
 The  DRD2 gene that encodes the D2 receptor has several 
well-characterized polymorphisms, some of which have been 
associated with diseases such as schizophrenia and depend-
ence. The TaqIA SNP has been extensively studied in rela-
tion to alcohol misuse. There is, however, little agreement 
whether it is [56-64] or is not [65-69] associated with alcohol 
dependence. This work is further complicated by some stud-
ies being limited to special populations [66, 68], limited to a 
single gender [61, 64], or broadened to additional psychiatric 
disorders [58, 60, 64]. Meta-analyses also disagree, with 
some finding an association with alcohol dependence [70, 
71] and others not [72]. The TaqIA story was further compli-
cated when it was found that the SNP, which is ca. 9 kbp 
downstream of the last exon of DRD2, is in fact in the coding 
sequence of a poorly characterized neighboring gene, an-
kyrin-repeat containing kinase 1 (ANKK1) [73]. Work in this 
area continues. 
CURRENT TRENDS IN METHAMPHETAMINE USE 
AND ABUSE 
  Abuse of methamphetamine (METH) is a growing inter-
national public health problem with an estimated 35 million 
users worldwide, including countries like Canada, China, 
Japan, Mexico, and USA [74]. It is thought that over half of 
the world’s METH consumers reside in Southeast Asia. In 
Mexico, the number of people admitted to treatment for psy-
chostimulant addiction from 3% in 1996 to 20% in 2006. 
METH is the most commonly synthesized illegal drug in the 
United States and has been cited by law enforcement offi-
cials as the leading cause of criminal problems in the coun-
try. A 2006 survey showed that 5.8% of Americans aged 12 
years or older used METH at least once [75]. There have 
been substantial increases in METH-related emergency room 
admissions at hospitals in the Southwest of the USA. 
  After taking the drug, users experience a sense of eupho-
ria, increased productivity, hypersexuality, decreased anxiety 
and increased energy. These effects can last for several 
hours. METH abuse is also associated with a number of 
negative which include acute toxicity, altered behavioral and 
cognitive functions, and neurological damage [76]. Inges-
tions of large doses of the drug can also cause more serious 
consequences that include life-threatening hyperthermia, 
renal and liver failure, cardiac arrhythmias, heart attacks, 
cerebrovascular hemorrhages, strokes and seizures. Chronic 
abuse of METH contributes to anxiety, depression, aggres-
siveness, social isolation, psychosis, mood disturbances, and 
psychomotor dysfunction. Withdrawal from METH can pro-
duce anhedonia, irritability, fatigue, impaired social func-
tioning, and intense craving for the drug [76]. Neuroimaging 
studies have revealed METH-induced neurodegenerative 
changes in the brains of human addicts [77]. These include 
persistent decreases in the levels of dopamine transporters 
(DAT) in various brain. Structural magnetic resonance imag-
ing (MRI) studies in METH addicts have documented sub-
stantial morphological changes in their brains [78]. 
  Studies in animal models have reported that METH can 
cause depletion of dopamine, serotonin, and of their metabo-
lites in the brain [79]. These abnormalities are associated 
with marked decreases in the DA and 5-HT transporters in 
various brain regions. These abnormalities are thought to be 
related to the production of oxygen-based radicals including 
superoxide radicals, hydrogen peroxide, and hydroxyl radi-
cals. Damage to mitochondria and abnormal metabolism of 
other reactive compounds might also play a role in causing 
METH-induced damage in monoaminergic terminals [79]. 
Some of the damage are prevented by pretreatment with do-
paminergic receptor blockers and trophic factors such as 
GDNF or BMP7 [80]. Another process that has shown to be 
protective involves administration of low doses for METH 
that are not toxic, suggesting that small doses of the drug can 
trigger molecular and cellular changes that render the brain 
refractory to its pro-oxidant properties [81]. If we can project 
this idea to the human condition, this process might explain 
why drug addicts do not develop signs and symptoms of 
Parkinsonism. 
  In summary, METH addiction is a major neuropsy-
chiatric problem. Research is under way in order to under-
stand the basic mechanisms involved in switching from ex-
posure to drug to being addicted to METH. These studies 
involve behavioral, cellular and molecular neurobiological 
approaches. It is hoped that understanding of the pathways 
involved will lead to better treatment approaches to the clini-
cal population of METH addicted individuals. 
TIME TO TAKE A CLOSER LOOK AT MDMA 
USE/ABUSE 
  MDMA became a popular drug in the USA in the 1970s 
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associated with "raves" and the youth dance culture and in 
the early 1990s reports of excessive use were restricted to 
case studies [82-85]. Early surveys suggested that use was 
limited [86, 87] and the seeming ability to control intake led 
to the belief that the drug had limited abuse potential [88, 89] 
did “not seem addictive” [90] and had “almost no potential 
to lead to dependence” [91]. In 1995, the Monitoring the 
Future survey in the USA indicated an increase in ecstasy 
use among high school students. Subsequent surveys indi-
cated an increase in prevalence rates through to 2001 fol-
lowed by a decrease. Current prevalence rates (2007) are at 
about 4% of high school students in the USA. The pattern of 
ecstasy use also appears to have changed quite considerably 
in more recent years. While most users consume MDMA 
relatively infrequently, increasingly the data indicate that 
many users consume MDMA frequently and in large 
amounts and some users met criteria for abuse and/or de-
pendence as measured by DSM. The changes being observed 
in MDMA use and abuse are reminiscent of those that were 
seen with cocaine in the 1980s. Cocaine was also not initially 
considered to be “addictive” [92], a conclusion that we now 
know is not true. Some cocaine users consume the drug in a 
compulsive manner that characterizes abuse. MDMA users 
have also been classified as either novice or light users, 
moderate users or heavy users based upon either length of 
time of use, number of pills typically ingested per use or 
total lifetime use. When one examines the use patterns, it 
becomes apparent that heavy users take more pills on each 
occasion [93-96]. Specifically, the number of tablets usually 
taken and the largest number of tablets ever taken on one 
occasion was largest in the subjects classified as heavy 
MDMA users. 
  There is considerable controversy about the extent of 
short- and long-term consequences of MDM use and abuse. 
We have several decades of preclinical research that has in-
vestigated self-administration and other models of drug 
abuse. This knowledge and paradigm development is being 
applied to the study of MDMA abuse to ultimately under-
stand the neurobiological mechanisms and the consequences 
of use and abuse of this drug. 
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